COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00354796
Recruitment Status : Unknown
Verified June 2011 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
First Posted : July 20, 2006
Last Update Posted : July 6, 2011
Information provided by:
Hadassah Medical Organization

Brief Summary:
We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.

Condition or disease
Acute Coronary Syndrome Venous Thromboembolism Atrial Fibrillation Hypercoagulability

Detailed Description:
Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin
Study Start Date : July 2006
Estimated Study Completion Date : October 2015

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients admitted to tertiary hospital

Inclusion Criteria:

  • treatment with enoxaparin

Exclusion Criteria:

  • no

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00354796

Layout table for location contacts
Contact: Mordechai Muszkat, MD 00-972-2-6776449

Layout table for location information
Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD    00 972 2 6776095   
Contact: hadas Lemberg, PhD    00 972 2 6777572   
Principal Investigator: Mordechai Muszkat, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Mordechai Muszkat, MD Hadassah University Hospital
Layout table for additonal information
Responsible Party: Mordechai Muszkat, Hadassah University Hospital Identifier: NCT00354796    
Other Study ID Numbers: enoxap-HMO-CTIL
First Posted: July 20, 2006    Key Record Dates
Last Update Posted: July 6, 2011
Last Verified: June 2011
Keywords provided by Hadassah Medical Organization:
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Acute Coronary Syndrome
Venous Thromboembolism
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Myocardial Ischemia
Vascular Diseases
Embolism and Thrombosis
Hematologic Diseases